
Pharma Services M&A Q4 2026 roundtable
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development and commercialisation lifecycle, with:
- Sami Hawwa, Managing Director and and part of the founding team at NewVale Capital
- Sabina Ouimet-Storrs, Principal at GHO Capital Partners
- James West, Managing Director, Head of Europe at Bourne Partners
Your host, Raman Sehgal, discusses the pharma and biopharma ecosystem with his guests, covering:
Which assumptions about pharma services investing they got wrong, and which ones they got right
The ongoing bid ask valuation gap, paused processes, and the increasingly creative ways deals are being structured
Which segments remain attractive, where investors are becoming more sceptical, and how to avoid getting caught up in market fads
The impact of tariffs, reshoring, potential overbuilding of capacity, and AI on investment decisions
Current sentiment across the market, and how optimistic they are heading into the year ahead
Sami Hawwa is a Managing Director at NewVale Capital, where he focuses on investments in the services and enabling technologies underpinning the life sciences industry. At NewVale, the investment focus spans the pharmaceutical value chain, from drug discovery and clinical development through manufacturing and commercialisation. Sami is actively involved in sourcing and executing new investments and partnering with management teams to accelerate growth, strengthen operations and build scalable, market leading businesses.
Sabina Ouimet Storrs is a Principal at GHO Capital, where she co leads the firm’s efforts in the biopharma subsector. She has more than a decade of experience investing in healthcare businesses across Europe and North America.
Since joining GHO in 2015, Sabina has partnered with management teams through periods of significant growth and transformation. She led two successful exits, DDC and Caprion, and currently serves on the board of Ardena. She works closely with leadership teams on strategy, value creation and growth, and particularly values the partnership side of the role.
Sabina began her career at PwC before moving into private equity at Fulcrum Capital in Toronto. She holds a Bachelor of Commerce from Dalhousie University and is a Chartered Professional Accountant.
Outside of work, she is mum to three young girls, who keep her negotiation skills sharp and her ego firmly in check.
James West leads Bourne Partners’ European business, bringing 15 years of M&A experience across pharmaceutical services and products. He has worked extensively with private equity funds, their portfolio companies and independent entrepreneurs in the sector, and has spent his professional career advising these groups on global M&A transactions from both London and New York.
Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Fler avsnitt från "Molecule to Market: Inside the outsourcing space"



Missa inte ett avsnitt av “Molecule to Market: Inside the outsourcing space” och prenumerera på det i GetPodcast-appen.








